ENLIVEN THERAPEUTICS, INC. Operating Cash Flow
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Operating Cash Flow of -$37.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.53M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.29M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.84M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$13.28M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$70.30M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$73.19M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$61.27M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$32.08M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$18.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$37.82M 10-Q · filed 2026-08-05 | -$53.66M derived: sum of 3 quarters · filed 2026-08-05 | -$66.94M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$19.29M 10-Q · filed 2026-05-07 | -$35.13M derived: sum of 2 quarters · filed 2026-05-07 | -$48.41M derived: sum of 3 quarters · filed 2026-05-07 | -$65.47M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$29.12M derived: sum of 2 quarters · filed 2026-03-03 | -$46.17M derived: sum of 3 quarters · filed 2026-08-05 | -$70.30M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$13.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$30.34M derived: sum of 2 quarters · filed 2026-08-05 | -$54.46M 10-Q · filed 2025-11-12 | -$71.67M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$17.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$41.18M 10-Q · filed 2026-08-05 | -$58.39M derived: sum of 3 quarters · filed 2026-08-05 | -$70.58M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$24.13M 10-Q · filed 2026-05-07 | -$41.33M derived: sum of 2 quarters · filed 2026-05-07 | -$53.52M derived: sum of 3 quarters · filed 2026-05-07 | -$73.96M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$17.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$29.40M derived: sum of 2 quarters · filed 2026-03-03 | -$49.83M derived: sum of 3 quarters · filed 2026-03-03 | -$73.19M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | -$12.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$32.63M derived: sum of 2 quarters · filed 2025-11-12 | -$55.99M 10-Q · filed 2025-11-12 | -$68.47M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$20.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$43.80M 10-Q · filed 2025-08-13 | -$56.28M derived: sum of 3 quarters · filed 2025-08-13 | -$72.17M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$23.36M 10-Q · filed 2025-05-14 | -$35.84M derived: sum of 2 quarters · filed 2025-05-14 | -$51.74M derived: sum of 3 quarters · filed 2025-05-14 | -$63.79M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$28.38M derived: sum of 2 quarters · filed 2025-03-13 | -$40.42M derived: sum of 3 quarters · filed 2025-03-13 | -$61.27M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$15.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$27.94M derived: sum of 2 quarters · filed 2024-11-13 | -$48.79M 10-Q · filed 2024-11-13 | -$56.93M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$12.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$32.89M 10-Q · filed 2024-08-13 | -$41.04M derived: sum of 3 quarters · filed 2024-08-13 | -$47.48M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$20.84M 10-Q · filed 2024-05-14 | -$28.99M derived: sum of 2 quarters · filed 2024-05-14 | -$35.44M derived: sum of 3 quarters · filed 2024-05-14 | -$42.56M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$14.59M derived: sum of 2 quarters · filed 2024-03-14 | -$21.72M derived: sum of 3 quarters · filed 2024-03-14 | -$32.08M 10-K · filed 2024-03-14 | -$35.57M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | -$6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$13.57M derived: sum of 2 quarters · filed 2023-11-09 | -$23.93M 10-Q · filed 2023-11-09 | -$33.69M 10-Q · filed 2022-10-25 | -$8.78M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$7.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$17.48M 10-Q · filed 2023-08-10 | -$29.49M 10-Q · filed 2022-08-03 | -$2.33M derived: sum of 3 quarters · filed 2023-08-10 | -$13.23M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$10.36M 10-Q · filed 2023-05-11 | -$17.16M 10-Q · filed 2022-05-06 | $4.79M derived: sum of 2 quarters · filed 2023-06-23 | -$6.11M derived: sum of 3 quarters · filed 2023-06-23 | -$16.48M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | $15.15M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $4.25M derived: sum of 2 quarters · filed 2023-06-23 | -$6.11M derived: sum of 3 quarters · filed 2023-06-23 | -$19.13M 8-K · filed 2023-06-23 | -$46.77M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | -$10.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$21.27M derived: sum of 2 quarters · filed 2022-10-25 | -$34.29M 10-Q · filed 2022-10-25 | -$42.55M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | -$10.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$23.39M 10-Q · filed 2022-08-03 | -$31.65M derived: sum of 3 quarters · filed 2022-08-03 | -$42.00M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | -$13.02M 10-Q · filed 2022-05-06 | -$21.29M derived: sum of 2 quarters · filed 2022-05-06 | -$31.64M derived: sum of 3 quarters · filed 2022-05-06 | -$40.89M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$18.61M derived: sum of 2 quarters · filed 2022-03-15 | -$27.87M derived: sum of 3 quarters · filed 2022-03-15 | -$37.40M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$10.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$19.60M derived: sum of 2 quarters · filed 2021-11-09 | -$29.13M 10-Q · filed 2021-11-09 | -$37.17M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$9.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$18.78M 10-Q · filed 2021-08-06 | -$26.82M derived: sum of 3 quarters · filed 2021-08-06 | -$33.10M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | -$9.53M 10-Q · filed 2021-05-11 | -$17.57M derived: sum of 2 quarters · filed 2021-05-11 | -$23.85M derived: sum of 3 quarters · filed 2021-05-11 | -$29.00M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | -$14.32M derived: sum of 2 quarters · filed 2021-03-05 | -$19.47M derived: sum of 3 quarters · filed 2021-03-05 | -$21.88M 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | -$6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$11.43M derived: sum of 2 quarters · filed 2020-11-05 | -$13.84M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | -$5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$7.55M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | -$2.41M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |